−0.015AUD
−3.10 MAUD
149.23 KAUD
181.25 M
About BIO-GENE TECHNOLOGY LTD
Sector
CEO
Tim Grogan
Headquarters
Melbourne
Website
Founded
1995
ISIN
AU000000BGT8
FIGI
BBG00HXMHVF4
Bio-Gene Technology Ltd. engages in the research and development of the next generation of novel insecticides, addressing the problems of insecticide resistance and toxicity. Its novel platform technology is based on occurring beta-triketones, a type of chemistry that may offer solutions for insect management control in animal health and crop protection as well as in public health applications. The company was founded on November 8, 1995 and is headquartered in Melbourne, Australia.
BGT Reverse H&S Pattern FormingBGT has just recently signed a partnership with Clarke - Public Health Mosquito Control and Aquatic Service company, a multi billion dollar world leader in their field. This partnership has validated the massive potential BGT's new mode of action holds.
The recent announcement was met with some op
BGT Gap Fill and bounce towards 17c - 21c channelBGT failed its contiunation of the falling wedge breakout last week due to macro economic conditions as did many stocks globally. BGT appeared to hit bottom as the fear selling was mostly absorbed.
The 14.5c gap (Red dotted lines) was filled and promptly bounced back to 16.5. R% back into the ove
BGT Break of Falling Wedge PatternBGT once again has returned into its 17c support channel, and is shaping up to breakout this week of the falling wedge pattern. Diminishing volumes and stifled seller pressure was met with an urgency in buying in the last few sessions which saw supply thinning and subsequent price increase.
R% was a
BGT Falling wedge on all time lowsWith a Market Cap of ~$12 million and cash in hand of $5.3 million, and prospective multi-billion dollar customers trialling their product, this spec is highly undervalued.
Falling wedge pattern with next to no volume exchanging hands below 11c. Safe entry here IMO.
DYOR
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BGT is 0.075 AUD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange BIO-GENE TECHNOLOGY LTD stocks are traded under the ticker BGT.
BIO-GENE TECHNOLOGY LTD is going to release the next earnings report on Aug 22, 2024. Keep track of upcoming events with our Earnings Calendar.
BGT stock is 0% volatile and has beta coefficient of 1.16. Check out the list of the most volatile stocks — is BIO-GENE TECHNOLOGY LTD there?
Yes, you can track BIO-GENE TECHNOLOGY LTD financials in yearly and quarterly reports right on TradingView.
BGT stock has risen by 7.14% compared to the previous week, the month change is a 31.58% rise, over the last year BIO-GENE TECHNOLOGY LTD has showed a 14.77% decrease.
BGT net income for the last quarter is −1.51 M AUD, while the quarter before that showed −1.13 M AUD of net income which accounts for −34.10% change. Track more BIO-GENE TECHNOLOGY LTD financial stats to get the full picture.
Today BIO-GENE TECHNOLOGY LTD has the market capitalization of 15.10 M, it has decreased by 13.33% over the last week.
No, BGT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BGT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIO-GENE TECHNOLOGY LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIO-GENE TECHNOLOGY LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIO-GENE TECHNOLOGY LTD stock shows the neutral signal. See more of BIO-GENE TECHNOLOGY LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIO-GENE TECHNOLOGY LTD EBITDA is −3.18 M AUD, and current EBITDA margin is −2.40 K%. See more stats in BIO-GENE TECHNOLOGY LTD financial statements.